HeartBeam, Inc. Stock

Equities

BEAT

US42238H1086

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:30:00 2024-04-24 pm EDT 5-day change 1st Jan Change
2.05 USD +0.49% Intraday chart for HeartBeam, Inc. +13.89% -12.77%
Sales 2024 * 100K Sales 2025 * 2.1M Capitalization 53.84M
Net income 2024 * -17M Net income 2025 * - EV / Sales 2024 * 538 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 25.6 x
P/E ratio 2024 *
-3.11 x
P/E ratio 2025 *
-3.47 x
Employees 15
Yield 2024 *
-
Yield 2025 *
-
Free-Float 71.83%
More Fundamentals * Assessed data
Dynamic Chart
HeartBeam, Inc. Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias CI
Transcript : HeartBeam, Inc., Q4 2023 Earnings Call, Mar 20, 2024
HeartBeam, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
HeartBeam, Inc. Announces First Patients Enrolled in Pivotal Study Evaluating HeartBeam's AIMIGo System for Synthesizing A 12-Lead ECG CI
HeartBeam, Inc. Receives Two New US Patents for Its Core Cardiac Monitoring Technology CI
HeartBeam, Inc. Announces Retirement of Richard Brounstein as Chief Financial Officer CI
HeartBeam, Inc. Unveils AI Program Designed to Deliver Unprecedented Personalized Cardiac Insights CI
Transcript : HeartBeam, Inc., Q3 2023 Earnings Call, Nov 14, 2023
HeartBeam, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Certain Warrants of HeartBeam, Inc. are subject to a Lock-Up Agreement Ending on 31-OCT-2023. CI
Certain Stock Options of HeartBeam, Inc. are subject to a Lock-Up Agreement Ending on 31-OCT-2023. CI
Certain Common Stock of HeartBeam, Inc. are subject to a Lock-Up Agreement Ending on 31-OCT-2023. CI
Heartbeam, Inc. Appoints Richa Gujarati as Senior Vice President, Product CI
Transcript : HeartBeam, Inc., Q2 2023 Earnings Call, Aug 10, 2023
HeartBeam, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
More news
1 day+0.49%
1 week+13.89%
Current month-5.96%
1 month-4.21%
3 months+15.82%
6 months+55.30%
Current year-12.77%
More quotes
1 week
1.90
Extreme 1.9
2.20
1 month
1.70
Extreme 1.7
2.31
Current year
1.35
Extreme 1.35
2.70
1 year
1.06
Extreme 1.06
3.74
3 years
1.06
Extreme 1.06
6.74
5 years
1.06
Extreme 1.06
6.74
10 years
1.06
Extreme 1.06
6.74
More quotes
Managers TitleAgeSince
Founder 70 14-12-31
President - 23-01-17
Chief Tech/Sci/R&D Officer - 23-09-25
Members of the board TitleAgeSince
Chairman 70 18-12-31
Director/Board Member 72 15-06-10
Director/Board Member 67 23-06-04
More insiders
Date Price Change Volume
24-04-24 2.05 +0.49% 13,599
24-04-23 2.04 +2.00% 28,831
24-04-22 2 +3.63% 35,564
24-04-19 1.93 -7.66% 79,498
24-04-18 2.09 -3.24% 42,260

Delayed Quote Nasdaq, April 24, 2024 at 04:30 pm EDT

More quotes
HeartBeam, Inc. is a cardiac technology company. The Company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease both inside and outside a healthcare facility setting. The Company is engaged in the development of its proprietary and patented Vector Electrocardiography (VECG) technology platform. Its VECG is capable of developing three-dimensional vector images of cardiac electrical activity by displaying the spatial locations of ECG waveforms. It has two patented products in development, such as HeartBeam AIMI and HeartBeam AIMIGo. HeartBeam AIMI is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack. HeartBeam AIMIGo is a credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.05 USD
Average target price
5 USD
Spread / Average Target
+143.90%
Consensus